Option Circle | $3,000,000 | (Mar 12, 2026)
Standard Kernel Co. | $20,000,000 | (Mar 12, 2026)
Chowbus | $81,000,000 | (Mar 12, 2026)
Certified by Founder
Lodge
Quell Therapeutics
start up
United Kingdom
- London, London
- 29/11/2021
- Series B
- $156,000,000
An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions.
Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.
- Industry Biotechnology Research
- Website https://quell-tx.com/
- LinkedIn https://www.linkedin.com/company/quell-therapeutics/about/
zymtrace | $12,200,000 | (Mar 12, 2026)
AgentMail (YC S25) | $6,000,000 | (Mar 12, 2026)
Ernesta Inc. | $20,000,000 | (Mar 12, 2026)
Translucent AI | $27,000,000 | (Mar 12, 2026)
Xscape Photonics Inc | $37,000,000 | (Mar 12, 2026)
Swarm Aero | $35,000,000 | (Mar 12, 2026)
anchr | $5,800,000 | (Mar 12, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)